Martina Deckert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3577295/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction. Journal of Experimental Medicine, 2000, 192, 393-404.	8.5	842
3	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	4.6	442
4	Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis. Annals of Neurology, 2002, 51, 311-318.	5.3	353
5	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncology, The, 2015, 16, e322-e332.	10.7	340
6	Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood, 2011, 117, 3140-3146.	1.4	284
7	T Cell–specific Inactivation of the Interleukin 10 Gene in Mice Results in Enhanced T Cell Responses but Normal Innate Responses to Lipopolysaccharide or Skin Irritation. Journal of Experimental Medicine, 2004, 200, 1289-1297.	8.5	283
8	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology,the, 2017, 4, e510-e523.	4.6	258
9	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
10	Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood, 2004, 103, 1869-1875.	1.4	164
11	Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia, 2011, 25, 1797-1807.	7.2	157
12	Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathologica, 2011, 122, 791-792.	7.7	151
13	Endothelial cellâ€derived angiopoietinâ€2 is a therapeutic target in treatmentâ€naive and bevacizumabâ€resistant glioblastoma. EMBO Molecular Medicine, 2016, 8, 39-57.	6.9	140
14	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology,the, 2016, 3, e388-e397.	4.6	128
15	Gp130-Dependent Astrocytic Survival Is Critical for the Control of Autoimmune Central Nervous System Inflammation. Journal of Immunology, 2011, 186, 6521-6531.	0.8	105
16	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro-Oncology, 2020, 22, 17-30.	1.2	94
17	Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. Journal of Cancer Research and Clinical Oncology, 1989, 115, 179-188.	2.5	93
18	Mutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in primary CNS lymphoma. Acta Neuropathologica, 2010, 120, 529-535.	7.7	86

#	Article	IF	CITATIONS
19	Current strategies in the diagnosis of diffuse large Bâ€cell lymphoma of the central nervous system. British Journal of Haematology, 2012, 156, 421-432.	2.5	77
20	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunology Research, 2019, 7, 1910-1927.	3.4	74
21	Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-κB- and STAT1-dependent chemokine production in astrocytes. Acta Neuropathologica, 2013, 126, 711-724.	7.7	73
22	Endogenous Interleukin-10 Is Required for Prevention of a Hyperinflammatory Intracerebral Immune Response in Listeria monocytogenes Meningoencephalitis. Infection and Immunity, 2001, 69, 4561-4571.	2.2	72
23	Interphase Cytogenetic Analysis of Lymphoma-Associated Chromosomal Breakpoints in Primary Diffuse Large B-Cell Lymphomas of the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2002, 61, 926-933.	1.7	70
24	Primary lymphoma of the central nervous system: just DLBCL or not?. Blood, 2009, 113, 7-10.	1.4	69
25	Diagnosis of leptomeningeal disease in diffuse large Bâ€cell lymphomas of the central nervous system by flow cytometry and cytopathology. European Journal of Haematology, 2010, 85, 520-528.	2.2	68
26	Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathologica, 2013, 126, 603-605.	7.7	64
27	Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathologica, 2012, 124, 905-906.	7.7	63
28	Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathologica, 2007, 114, 271-276.	7.7	61
29	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathologica, 2014, 127, 175-188.	7.7	58
30	Chromosomal Translocations Fusing the <i>BCL6</i> Gene to Different Partner Loci Are Recurrent in Primary Central Nervous System Lymphoma and May Be Associated With Aberrant Somatic Hypermutation or Defective Class Switch Recombination. Journal of Neuropathology and Experimental Neurology, 2006, 65, 776-782.	1.7	53
31	Hypertrophy of the lumbar ligamentum flavum is associated with inflammation-related TGF-Î ² expression. Acta Neurochirurgica, 2011, 153, 134-141.	1.7	53
32	Primary lymphoma of the central nervous system—a diagnostic challenge. Hematological Oncology, 2014, 32, 57-67.	1.7	52
33	Recurrent Inactivation of the PRDM1 Gene in Primary Central Nervous System Lymphoma. Journal of Neuropathology and Experimental Neurology, 2008, 67, 720-727.	1.7	51
34	Absence of Immunoglobulin Class Switch in Primary Lymphomas of the Central Nervous System. American Journal of Pathology, 2005, 166, 1773-1779.	3.8	47
35	Astrocytic <scp>F</scp> as ligand expression is required to induce <scp>T</scp> â€cell apoptosis and recovery from experimental autoimmune encephalomyelitis. European Journal of Immunology, 2013, 43, 115-124.	2.9	47
36	The Diagnosis and Treatment of Primary CNS Lymphoma. Deutsches Ärzteblatt International, 2018, 115, 419-426.	0.9	46

#	Article	IF	CITATIONS
37	Transcriptional Profiling of the Nuclear Factor-κB Pathway Identifies a Subgroup of Primary Lymphoma of the Central Nervous System With Low BCL10 Expression. Journal of Neuropathology and Experimental Neurology, 2007, 66, 230-237.	1.7	44
38	The deubiquitinase OTUB1 augments NF-κB-dependent immune responses in dendritic cells in infection and inflammation by stabilizing UBC13. Cellular and Molecular Immunology, 2021, 18, 1512-1527.	10.5	40
39	Neuronal gp130 Expression Is Crucial to Prevent Neuronal Loss, Hyperinflammation, and Lethal Course of Murine Toxoplasma Encephalitis. American Journal of Pathology, 2012, 181, 163-173.	3.8	37
40	Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins. Journal of Immunology, 2015, 195, 1312-1319.	0.8	37
41	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	5.2	37
42	Toll-Like Receptors Promote Inflammation in Idiopathic Inflammatory Myopathies. Journal of Neuropathology and Experimental Neurology, 2012, 71, 855-867.	1.7	35
43	Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. International Journal of Molecular Sciences, 2018, 19, 1090.	4.1	34
44	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. Journal of Nuclear Medicine, 2020, 61, 1765-1771.	5.0	34
45	Oligodendrocytes Enforce Immune Tolerance of the Uninfected Brain by Purging the Peripheral Repertoire of Autoreactive CD8+ T Cells. Immunity, 2012, 37, 134-146.	14.3	32
46	<scp>OTUB</scp> 1 inhibits <scp>CNS</scp> autoimmunity by preventing <scp>IFN</scp> â€î³â€induced hyperactivation of astrocytes. EMBO Journal, 2019, 38, .	7.8	31
47	Array-based DNA methylation profiling of primary lymphomas of the central nervous system. BMC Cancer, 2009, 9, 455.	2.6	30
48	Molecular Characterization of <i>BCL6</i> Breakpoints in Primary Diffuse Large Bâ€cell Lymphomas of the Central Nervous System Identifies <i>GAPD</i> as Novel Translocation Partner. Brain Pathology, 2003, 13, 534-538.	4.1	29
49	A20 expression in dendritic cells protects mice from LPSâ€induced mortality. European Journal of Immunology, 2015, 45, 818-828.	2.9	28
50	OTUB1 prevents lethal hepatocyte necroptosis through stabilization of c-IAP1 during murine liver inflammation. Cell Death and Differentiation, 2021, 28, 2257-2275.	11.2	27
51	VH gene analysis of primary CNS lymphomas. Journal of the Neurological Sciences, 2005, 228, 143-147.	0.6	26
52	CYLD Enhances Severe Listeriosis by Impairing IL-6/STAT3-Dependent Fibrin Production. PLoS Pathogens, 2013, 9, e1003455.	4.7	25
53	KLF4K409Q–mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment. Acta Neuropathologica Communications, 2020, 8, 41.	5.2	25
54	Molecular Mimicry between Neurons and an Intracerebral Pathogen Induces a CD8 T Cell-Mediated Autoimmune Disease. Journal of Immunology, 2008, 180, 8421-8433.	0.8	24

#	Article	IF	CITATIONS
55	Immunoglobulin Repertoire of Primary Lymphomas of the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1116-1125.	1.7	23
56	ITIH5 induces a shift in TGFâ€Î² superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death. Molecular Carcinogenesis, 2018, 57, 167-181.	2.7	21
57	Absence of simian virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 436-438.	2.8	20
58	IL-10, IL-4, and STAT6 Promote an M2 Milieu Required for Termination of P0106-125-Induced Murine Experimental Autoimmune Neuritis. American Journal of Pathology, 2014, 184, 2627-2640.	3.8	20
59	Human herpes virus-8 is not associated with primary central nervous system lymphoma in HIV-negative patients. Acta Neuropathologica, 2001, 102, 489-495.	7.7	19
60	CD4 T Cells Mediate Axonal Damage and Spinal Cord Motor Neuron Apoptosis in Murine P0106–125-Induced Experimental Autoimmune Neuritis. American Journal of Pathology, 2008, 173, 93-105.	3.8	19
61	A tissueâ€specific screen of ceramide expression in aged mice identifies ceramide synthaseâ€1 and ceramide synthaseâ€5 as potential regulators of fiber size and strength in skeletal muscle. Aging Cell, 2020, 19, e13049.	6.7	18
62	Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma. Neurology, 2020, 95, e3138-e3144.	1.1	18
63	Distinct transcriptomic changes in E14.5 mouse skeletal muscle lacking RYR1 or Cav1.1 converge at E18.5. PLoS ONE, 2018, 13, e0194428.	2.5	18
64	Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. Blood, 2012, 120, 302-302.	1.4	17
65	Beyond the 3′UTR binding-microRNA-induced protein truncation via DNA binding. Oncotarget, 2018, 9, 32855-32867.	1.8	17
66	Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases. Neuro-Oncology, 2022, 24, 1331-1340.	1.2	17
67	Interleukin-1 Receptor Type 1 Is Essential for Control of Cerebral but Not Systemic Listeriosis. American Journal of Pathology, 2007, 170, 990-1002.	3.8	16
68	Bi-allelic mutations in uncoordinated mutant number-45 myosin chaperone B are a cause for congenital myopathy. Acta Neuropathologica Communications, 2019, 7, 211.	5.2	15
69	Protective <i>Toxoplasma gondii</i> -Specific T-Cell Responses Require T-Cell-Specific Expression of Protein Kinase C-Theta. Infection and Immunity, 2010, 78, 3454-3464.	2.2	14
70	The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma. Haematologica, 2021, 106, 708-717.	3.5	14
71	Gene profiling of embryonic skeletal muscle lacking type I ryanodine receptor Ca2+ release channel. Scientific Reports, 2016, 6, 20050.	3.3	13
72	Long-Time Course of Idiopathic Small Fiber Neuropathy. European Neurology, 2018, 79, 161-165.	1.4	13

#	Article	IF	CITATIONS
73	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. Blood, 2016, 128, 511-511.	1.4	13
74	Regulation of the Inflammatory Response to Staphylococcus aureus-Induced Brain Abscess by Interleukin-10. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1046-1057.	1.7	11
75	Preferential Expression of Truncated Isoforms of FOXP1 in Primary Central Nervous System Lymphoma. Journal of Neuropathology and Experimental Neurology, 2009, 68, 972-976.	1.7	11
76	Dual role of B cells with accelerated onset but reduced disease activity in P0106–125-induced experimental autoimmune neuritis of IgH0/0 mice. Acta Neuropathologica, 2010, 120, 667-681.	7.7	11
77	Somatic mutations altering Tyr641 of EZH2 are rare in primary central nervous system lymphoma. Leukemia and Lymphoma, 2010, 51, 2135-2136.	1.3	10
78	Papillary tumors of the pineal region: a novel therapeutic option—stereotactic 125iodine brachytherapy. Journal of Neuro-Oncology, 2012, 109, 99-104.	2.9	10
79	Mechanisms of Intracerebral Lymphoma Growth Delineated in a Syngeneic Mouse Model of Central Nervous System Lymphoma. Journal of Neuropathology and Experimental Neurology, 2013, 72, 325-336.	1.7	10
80	Arrayâ€based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non NS diffuse large Bâ€cell lymphomas. Genes Chromosomes and Cancer, 2019, 58, 66-69.	2.8	10
81	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Journal of Molecular Diagnostics, 2020, 22, 1300-1307.	2.8	9
82	Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding. Oncotarget, 2017, 8, 110118-110132.	1.8	9
83	Listeriosis in pregnancy: case report and retrospective study. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 321-323.	1.5	8
84	Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 756-760.	1.9	8
85	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System. Cancers, 2021, 13, 6334.	3.7	8
86	FET PET in Primary Central Nervous System Vasculitis. Clinical Nuclear Medicine, 2018, 43, e322-e323.	1.3	7
87	Enteric Murine Ganglionitis Induced by Autoimmune CD8 T Cells Mimics Human Gastrointestinal Dysmotility. American Journal of Pathology, 2019, 189, 540-551.	3.8	7
88	Listeria monocytogenes (delta-actA mutant) infection in tumor necrosis factor receptor p55-deficient neonatal mice. Microbial Pathogenesis, 2010, 49, 186-195.	2.9	6
89	Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine. Case Reports in Oncology, 2020, 13, 35-42.	0.7	6
90	Endogenous II10 Alleviates the Systemic Antiviral Cellular Immune Response and T Cell–Mediated Immunopathology in Select Organs of Acutely LCMV-Infected Mice. American Journal of Pathology, 2015, 185, 3025-3038.	3.8	5

#	Article	IF	CITATIONS
91	Protective dendritic cell responses against listeriosis induced by the short form of the deubiquitinating enzyme CYLD are inhibited by fullâ€length CYLD. European Journal of Immunology, 2015, 45, 1366-1376.	2.9	5
92	Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors. Strahlentherapie Und Onkologie, 2015, 191, 936-944.	2.0	5
93	TLR signals license CD8 TÂcells to destroy oligodendrocytes expressing an antigen shared with a <i>Listeria</i> pathogen. European Journal of Immunology, 2019, 49, 413-427.	2.9	5
94	A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry. Cancers, 2020, 12, 1732.	3.7	5
95	Costimulatory Molecule CD40 Is Essential for Myelin Protein 0 Peptide 106–125–Induced Experimental Autoimmune Neuritis in Mice. Journal of Neuropathology and Experimental Neurology, 2014, 73, 454-466.	1.7	4
96	Toll-Like Receptor 2, Toll-Like Receptor 4, Myeloid Differentiation Response Gene 88, and Toll–IL-1 Receptor Domain-Containing Adaptor-Inducing Interferon-γ (TRIF) Selectively Regulate Susceptibility of P0106-125-Induced Murine Experimental Autoimmune Neuritis. American Journal of Pathology, 2017, 187, 42-54	3.8	4
97	Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTXâ€based regimens in clinical routine. European Journal of Haematology, 2021, 107, 202-210.	2.2	4
98	CD8 T cell–Derived Perforin and TNF-α Are Crucial Mediators of Neuronal Destruction in Experimental Autoimmune Enteric Ganglionitis. American Journal of Pathology, 2021, 191, 1064-1076.	3.8	4
99	Intracranial Ependymoma: Long-Term Results in a Series of 21 Patients Treated with Stereotactic 125Iodine Brachytherapy. PLoS ONE, 2012, 7, e47266.	2.5	4
100	Solitary Plasmacytoma Presenting as an Intramedullary Mass of the Cervical Cord. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2013, 74, e13-e17.	0.8	3
101	Absence of Lymphatic Vessels in PCNSL May Contribute to Confinement of Tumor Cells to the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2016, 75, 499-502.	1.7	3
102	Clinical Characteristics and Magnetic Resonance Imaging–Based Prediction of the KLF4 Mutation in Meningioma. World Neurosurgery, 2021, 154, e665-e670.	1.3	3
103	An unusual case of optic neuritis. Journal of the Neurological Sciences, 2011, 304, 138-141.	0.6	2
104	CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma. Blood, 2019, 134, 2900-2900.	1.4	1
105	Response to Comment on "Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteinsâ€: Journal of Immunology, 2015, 195, 4550-4551.	0.8	0
106	CBMT-25. THE KLF4K409Q MUTATION IN MENINGIOMA IMPAIRS HIF-1Î [°] DEGRADATION AND CAN BE HARNESSED FOR TARGETED THERAPY. Neuro-Oncology, 2019, 21, vi38-vi38.	1.2	0
107	Infektionen des ZNS. , 2012, , 303-330.		0
108	Lymphome des Zentralnervensystems. , 2019, , 851-859.		0

#	Article	IF	CITATIONS
109	Novel Form of Congenital Myopathy Caused by Biallelic Mutations in Uncoordinated Mutant Number-45 Myosin Chaperone B. , 2021, 52, .		0
110	NIMG-27. REGORAFENIB RESPONSE ASSESSMENT USING FET PET IN PATIENTS WITH PROGRESSIVE GLIOMA. Neuro-Oncology, 2021, 23, vi134-vi134.	1.2	0
111	NIMG-20. DIFFERENTIATION OF TREATMENT-RELATED CHANGES FROM TUMOR PROGRESSION FOLLOWING BRACHYTHERAPY IN PATIENTS WITH WHO II AND III GLIOMAS USING FET PET. Neuro-Oncology, 2021, 23, vi132-vi132.	1.2	0